Author: OurCrowd

Conquering the Term Sheet: Everything you need to know about deal terms (Part 2)

Conquering the Term Sheet: Everything you need to know about deal terms (Part 2)

May 21, 2015 | , ,

Yesterday, we held the 2nd installment of OurCrowd’s educational series on how professional investors analyze and construct terms and conditions for their investments. Missed Part 1? View it here. On this week’s Q&A session, we continue to explore the fundamentals of deal terms in startup investing, discussing how to: Understand the basics of deal terms, from full ratchet to anti-dilution Get an insider’s view of crafting deal terms in startup investing Learn what to look for in a term sheet from seed stage to pre-IPO ::::::::::::::::::::::::::::::::: To view the 3rd and final installment of our 3 part educational series on deal terms, click here. ::::::::::::::::::::::::::::::::: To stay updated on future events and the best news from the Startup Nation, sign up for our newsletter, email us, and follow us on social media.   View the FULL program Download/view the presentation [xyz-ihs...

Read More

OurCrowd’s portfolio company ReWalk featured in The Times of Israel

May 20, 2015 | ,

OurCrowd portfolio company ReWalk was featured in The Times of Israel, an English-language news website covering Israel, the region & the Jewish world. ReWalk is the developer of the FDA approved ReWalk exoskeleton device, providing paraplegics with an independent, natural walking experience that provides them numerous social, psychological, and physical benefits. For quadriplegics, losing the use of their legs is not the end of their problems, according to ReWalk CFO Kevin Hirschberger. “People with spinal cord injuries who are paralyzed below the waist have the same physical issues as everyone else, such as gaining weight if they eat too much and don’t exercise. With our ReWalk exoskeleton, patients can get the exercise their body needs, preventing severe conditions like heart problems, osteoporosis, kidney disease, and much more,” said Hirschberger. ReWalk raised $1,320,000 from OurCrowd investors in June 2013. Read more on The Times of...

Read More
All your questions, answered: 8 things to know about the medical cannabis industry [AMA with Dr. Morris Laster]

All your questions, answered: 8 things to know about the medical cannabis industry [AMA with Dr. Morris Laster]

May 20, 2015 | , ,

Medical cannabis is the next frontier of medtech investing, forecasted to become a $35 billion industry by 2020. How are the challenges of this industry being resolved? Your questions, answered: OurCrowd presents our first investor AMA (“ask me anything”) with medtech advisor, Venture Partner and 25-year industry veteran Dr. Morris Laster. Below, Dr. Laster addresses medical cannabis, providing answers and insight into the industry as well as the medtech advances made by Syqe Medical, developers of the world’s first meter-dosed botanical inhaler and OurCrowd’s current investment opportunity. Missed the live AMA? Have more queries about the medical cannabis industry? Don’t let your questions go unanswered!  Leave a comment below and we’ll answer them! —————- About Dr. Laster Dr. Laster is a physician with over 25 years of experience in the biopharmaceutical industry and with expertise in identification, development and management of advanced biomedical drugs and technologies. Dr. Laster is the Venture Partner responsible for Medtech investments at OurCrowd; he has founded and/or managed six companies that have gone public in the US, UK and Israel. He invented a novel device to access the circulatory system through the bone...

Read More

OurCrowd’s portfolio company Global Kinetics featured in Business Insider

May 19, 2015 | ,

OurCrowd portfolio company Global Kinetics was featured in Business Insider, an American business and technology news website. Global Kinetics’ lead product, the Parkinson’s KinetiGraph™ movement recording, is a unique and useful tool for neurologists in the management of movement disorders, such as Parkinson’s Disease. Israeli equity crowdfunding platform OurCrowd has closed Australia’s single largest equity crowdfunding round – $1.5 million for private Australian mobile health technology company Global Kinetics Corporation. The money is for GKC to commercialise the Parkinson’s KinetiGraph, used by doctors to assess and manage the symptoms of Parkinson’s disease. The funding will help the company’s US expansion, following recent FDA clearance. Global Kinetics raised $1,185,246 from OurCrowd investors in February 2015. Read more on Business...

Read More